Skip to content
Research Article Open access CC BY 4.0

Neoadjuvant Chemoradiotherapy and Chemotherapy in Patients with Locally Advanced Rectal Cancer

Alia M. Attia, Marwa I. Abdelgawad, Hussein Fakhry, Ahmed Soliman, Noha M. Attia

Journal of Cancer and Tumor International · pp. 1–13 · Published 10 Nov 2015

10.9734/JCTI/2016/22520

Abstract

Aims: Evaluate the role of neoadjuvant chemoradiotherapy (CRT) followed by an additional  cycle of chemotherapy and total mesorectal excision (TME) in patients with locally advanced rectal cancer on the rate of pathologic complete response (pCR) and tumor downstaging, their impact on survival and evaluation of treatment related toxicity and surgical complications. Patients and Methods: This prospective phase II trial included 73 patients with histopathologically proven non metastatic rectal adenocarcinoma referred from or admitted at Surgical Oncology Department, Radiotherapy Department, South Egypt Cancer Institute, and Clinical Oncology Department, Assiut University, Egypt, from March 2012 to September 2013. Radiotherapy (1.8 Gy, 5 days a week over 5 weeks, total dose 50.4 Gy, 3 D conformational technique) was given in combination with intravenous oxaliplatin 50 mg/m2 once weekly for 5 weeks and oral capecitabine 825 mg/m2 twice daily on each day of radiation. After completion of CRT, patients received an additional cycle of chemotherapy consisted of oxaliplatin (130 mg/m2 on day 1) and capecitabine (825 mg/m2, twice per day from day 1 to day 14). Surgery was performed 6–8 weeks after completion of chemoradiotherapy. Results: Seventy patients (95.9%) underwent surgery. Postoperative pathologic assessment showed an overall downstaging rate of 78.1%, while 16 patients (21.9%) had stationary disease. Complete pathologic response was achieved in 11 patients (15.1%). No tumor progression has been observed. After median follow up period of 26 months (7-30 months), the 2-year overall survival (OS) was 88%, recurrence free survival was 88.7% and distant metastasis free survival was 93.9%. Lower pathologic tumor stage was significantly associated with better OS (P = .002) and recurrence-free survival (P = .001), while pathologic nodal stage and TRG had no significant difference in overall survival, recurrence free survival or distant metastasis free survival. Forty-one patients (56.2%) experienced grade 1-2 toxicity and 5 patients (6.8%) experienced grade 3 toxicity.  Conclusion: Neoadjuvant CRT and one cycle of chemotherapy followed by TME is effective with pCR of 15.1% and overall downstaging rate of 78.1%. In addition to favorable toxicity profile (lower grade 3 and 4 toxic effects as 3 patients developed grade 3 diarrhea and 2 patients developed grade 3 hematological toxicity and  lower rate of Grade 1 – 2 diarrhea ; 28.8%) and outcome.  

Neoadjuvant radiotherapy chemotherapy surgical operation rectal cancer

References (31)

  1. 1 Toxicity and response criteria of the Eastern Cooperative Oncology Group [DOI]
  2. 2 Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer [DOI]
  3. 3 Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer [DOI]
  4. 4 Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data [DOI]
  5. 5 Pathological features of rectal cancer after preoperative radiochemotherapy [DOI]
  6. 6 Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence Rate [DOI]
  7. 7 Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer [DOI]
  8. 8 Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial [DOI]
  9. 9 The prognostic inhomogeneity in pT3 rectal carcinomas [DOI]
  10. 10 Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer [DOI]
  11. 11 Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0–04 Phase II Trial [DOI]
  12. 12 Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer [DOI]
  13. 13 Changing strategy for rectal cancer is associated with improved outcome [DOI]
  14. 14 A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer [DOI]
  15. 15 Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer [DOI]
  16. 16 Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation [DOI]
  17. 17 Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3–T4 unresectable rectal cancer: a phase II IATTGI study [DOI]
  18. 18 Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group [DOI]
  19. 19 Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancer [DOI]
  20. 20 The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery [DOI]
  21. 21 Addition of Oxaliplatin to Continuous Fluorouracil, l -Folinic Acid, and Concomitant Radiotherapy in Rectal Cancer: The Lyon R 97-03 Phase I Trial [DOI]
  22. 22 Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial [DOI]
  23. 23 Rectal cancer multidisciplinary management: Evidences and future landscape [DOI]
  24. 24 A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer [DOI]
  25. 25 Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: Four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response [DOI]
  26. 26 Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study [DOI]
  27. 27 Addition of oxaliplatin to neo-adjuvant radiochemotherapy for irresectable rectal cancer, a phase I study.
  28. 28 Preoperative (preop) radiotherapy (RT) ± 5 FU/folinic acid (FA) in T3–4 rectal cancers: results of the FFCD 9203 randomized trial [DOI]
  29. 29 The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials [DOI]
  30. 30 Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer [DOI]
  31. 31 Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC) [DOI]

Cited by 2

Advances in Radiotherapy for Locally Advanced Rectal Cancer

晓萌 纪 · Advances in Clinical Medicine · 2018

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

55

Page views

0

PDF downloads

18

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.